Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lida A Mina

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Nature Reviews. Clinical Oncology|April 20, 2011
Rethinking the metastatic cascade as a therapeutic targetLida A Mina, George W Sledge
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2023
Therapy-related Myeloid Neoplasms Following PARP Inhibitors-LetterFelipe Batalini, Lida A Mina, Alain Mina
Chirurgia (Bucharest, Romania : 1990)|December 30, 2021
Personalized Breast Cancer Risk Assessment: Incorporation of Genetic and High-Risk Factorson Breast Cancer Risk and ManagementJennifer M Siettmann, Banu Arun, Justin Gasparini, et al.
Breast Cancer (Dove Medical Press)|February 27, 2020
Immunotherapy for the Treatment of Breast Cancer: Emerging New DataLida A Mina, Shannon Lim, Shakeela W Bahadur, et al.
Academic Radiology|December 19, 2020
A Breast Radiology Department-operated, Proactive Same-day Program Identifies Pathogenic Breast Cancer Mutations in Unaffected WomenVilert A Loving, Rebecca C Luiten, Jennifer M Siettmann, et al.
Investigational New Drugs|July 2, 2013
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109Lida A Mina, Menggang Yu, Cynthia Johnson, et al.
Breast Cancer Research : BCR|September 15, 2011
Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patientsHitesh N Appaiah, Chirayu P Goswami, Lida A Mina, et al.
Cell|February 29, 2020
Precise and Programmable Detection of Mutations Using Ultraspecific RiboregulatorsFan Hong, Duo Ma, Kaiyue Wu, et al.
Cell|October 30, 2020
Precise and Programmable Detection of Mutations Using Ultraspecific RiboregulatorsFan Hong, Duo Ma, Kaiyue Wu, et al.
Chinese Clinical Oncology|May 22, 2023
Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysisFelipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Nature Reviews. Clinical Oncology|April 20, 2011
Rethinking the metastatic cascade as a therapeutic targetLida A Mina, George W Sledge
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2023
Therapy-related Myeloid Neoplasms Following PARP Inhibitors-LetterFelipe Batalini, Lida A Mina, Alain Mina
Chirurgia (Bucharest, Romania : 1990)|December 30, 2021
Personalized Breast Cancer Risk Assessment: Incorporation of Genetic and High-Risk Factorson Breast Cancer Risk and ManagementJennifer M Siettmann, Banu Arun, Justin Gasparini, et al.
Breast Cancer (Dove Medical Press)|February 27, 2020
Immunotherapy for the Treatment of Breast Cancer: Emerging New DataLida A Mina, Shannon Lim, Shakeela W Bahadur, et al.
Academic Radiology|December 19, 2020
A Breast Radiology Department-operated, Proactive Same-day Program Identifies Pathogenic Breast Cancer Mutations in Unaffected WomenVilert A Loving, Rebecca C Luiten, Jennifer M Siettmann, et al.
Investigational New Drugs|July 2, 2013
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109Lida A Mina, Menggang Yu, Cynthia Johnson, et al.
Breast Cancer Research : BCR|September 15, 2011
Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patientsHitesh N Appaiah, Chirayu P Goswami, Lida A Mina, et al.
Cell|February 29, 2020
Precise and Programmable Detection of Mutations Using Ultraspecific RiboregulatorsFan Hong, Duo Ma, Kaiyue Wu, et al.
Cell|October 30, 2020
Precise and Programmable Detection of Mutations Using Ultraspecific RiboregulatorsFan Hong, Duo Ma, Kaiyue Wu, et al.
Chinese Clinical Oncology|May 22, 2023
Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysisFelipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, et al.
Pageof 2